Overview

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Status:
Active, not recruiting

Trial end date:
2030-12-30

Target enrollment:

Participant gender:

Summary

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

Phase:

Phase 3

Details

Lead Sponsor:

Clovis Oncology, Inc.

Collaborators:

Bristol-Myers Squibb
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Foundation Medicine
Gynecologic Oncology Group

Treatments:

Antibodies, Monoclonal
Nivolumab
Rucaparib